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Abstract
The peripherally expressed voltage-gated sodium NaV1.7 (gene SCN9A) channel boosts small 
stimuli to initiate firing of pain-signaling dorsal root ganglia (DRG) neurons and facilitates 
neurotransmitter release at the first synapse within the spinal cord. Mutations in SCN9A produce 
distinct human pain syndromes. Widely acknowledged as a “gatekeeper” of pain, NaV1.7 has been 
the focus of intense investigation but, to date, no NaV1.7-selective drugs have reached the clinic. 
Elegant crystallographic studies have demonstrated the potential of designing highly potent and 
selective NaV1.7 compounds but their therapeutic value remains untested. Transcriptional 
silencing of NaV1.7 by a naturally expressed antisense transcript has been reported in rodents and 
humans but whether this represents a viable opportunity for designing NaV1.7 therapeutics is 
currently unknown. The demonstration that loss of NaV1.7 function is associated with 
upregulation of endogenous opioids and potentiation of mu- and delta-opioid receptor activities, 
suggests that targeting only NaV1.7 may be insufficient for analgesia. However, the link between 
opioid-dependent analgesic mechanisms and function of sodium channels and intracellular 
sodium-dependent signaling remains controversial and disputed. Thus, additional new targets - 
regulators, modulators - are needed. In this context, we mine the literature for the known 
interactome of NaV1.7 with a focus on protein interactors that affect the channel’s trafficking or 
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link it to opioid signaling. As a case study, we present antinociceptive evidence of allosteric 
regulation of NaV1.7 by the cytosolic collapsin response mediator protein 2 (CRMP2). Throughout 
discussions of these possible new targets, we offer thoughts on the therapeutic implications of 
modulating NaV1.7 function in chronic pain.
Graphical Abstract
1. NaV1.7 – an introduction to the “gatekeeper” of pain
Physiological pain is largely unpleasant and results from actual or potential tissue damage. 
The emotional and sensory experience of pain is recognized by the International Association 
for the Study of Pain as a key response that warns of ensuing danger. Chronic pain, however, 
contrasts with the biological usefulness of physiological pain, and persists past the point of 
normal healing to adversely affect 20% of the world’s population [1]. In the United States, 
chronic pain strains the economy to the value of 635 billion dollars per year [2], exceeding 
annual costs of several priority health conditions: heart disease ($309 billion), cancer ($243 
billion) and diabetes ($188 billion). Inevitably then, pain therapy is an industry requiring 
considerable attention.
In the last several decades, the voltage-gated sodium channel (VGSC) subtype NaV1.7 has 
been implicated as an important target in the nociceptive pathway [3, 4]. The protein belongs 
to a family of VGSCs which gate open in response to voltage and control Na+ ion influx 
during the rising phase of the action potentials that underlies all neuronal transmission [5]. 
Unique gating properties and tissue-level expression patterns and levels of NaV1.7 place the 
channel in a position to regulate pain signaling [4]. To-date, nine genes coding for voltage-
gated sodium channel α pores have been reported – NaV1.1-NaV1.9 [6, 7]. These have been 
broadly classified by their pharmacology and kinetics with members NaV1.1–NaV1.4 and 
NaV1.6–NaV1.7 being sensitive to channel block by tetrodotoxin (TTX-sensitive) and 
displaying rapid inactivation that typically occurs within 5–10 milliseconds. NaV1.5, NaV1.8 
and NaV1.9 are TTX-resistant and have much slower inactivation kinetics that produce 
persistent currents for up to several hundred milliseconds [8].
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Dysfunction of some sodium channels, including NaV1.7, is linked to painful human 
disorders [9]. Peripheral pain stimuli are transmitted along dorsal root ganglia (DRG) 
neurons making these long bipolar neurons that span from the extremities to the spinal cord 
an important target for intervention of pain. Variable expression levels for numerous VGSC 
isoforms and the diverse types of sensory information conveyed, play a strong role in 
determining the constituents of a DRG’s intracellular molecular biome [10]. Furthermore, 
differential VGSC expression and sensory input are linked to DRG cell body size. Large 
diameter (> 30 μm cell body) DRGs are predominately myelinated Aα/β fibers that transmit 
proprioceptive and touch information. This contrasts with smaller diameter (< 30 μm cell 
body) DRGs that are predominantly Aδ and C-fibers transmitting pain information. While 
these sizes are relevant for rat DRGS, this relationship is maintained in human DRGs as well 
[11]. Small and medium DRGs have lower expression of NaV1.1 and NaV1.6 and very high 
levels of NaV1.7, NaV1.8 and NaV1.9 [10]. Knowledge of this relationship between DRG 
size and VGSC isoform expression patterns better informs therapeutic development and 
allows for drug discovery efforts to more intentionally pursue strategies that limit effects on 
these acknowledged off-target sites.
NaV1.7 has been identified as the dominant contributor to sodium currents among TTX-S 
subtype channels in small to medium sized DRGs representing nearly 80% of TTX-S current 
[12]. High NaV1.7 expression in these cells is correlated by high signal of NaV1.7 
immunolabeling in small DRG cell bodies, projections to spinal cord, axons, and peripheral 
terminals in the dermis [13]. In guinea pigs, small cell body C-fibers exhibited augmented 
NaV1.7 expression compared to medium or large cell body counterparts [14]. Further 
examination revealed that this augmented NaV1.7 expression was also predictive of DRGs’ 
nociceptive response, further corroborating NaV1.7’s role as a pain-modifying channel [14].
Inevitably then, NaV1.7 mutations are related to a variety of painful phenotypes in addition 
to painless ones. Gain-of-function mutations underlie painful diseases like inherited 
erythromelalgia (IEM), paroxysmal extreme pain disorder (PEPD) [15–17], and a NaV1.7-
mediated variety of small fiber neuropathy (SFN) [18, 19]. The exact opposite effect on pain 
has been observed within patients harboring loss-of-function NaV1.7 mutations. These 
individuals exhibit congenital insensitivity (CIP) to pain and completely lack thermal and 
mechanical pain thresholds [20]. In addition to pain insensitivity, NaV1.7 loss-of-function 
mutations produce anosmia, a loss of sense of smell [21], and variable cases of epilepsy 
[22]. The high expression of NaV1.7 in nociceptive DRGs and phenotypes of human patients 
with NaV1.7 mutations underscores the importance of this specific voltage-gated sodium 
channel subtype in pain and has led many researchers to study NaV1.7 in pain models.
2. Progress in drug discovery targeting NaV1.7 – unfulfilled promises
The historical shortcomings of drugs targeting NaV1.7 has been extensively documented in 
thorough reviews [23, 24], with most concluding that in regards to therapeutic targeting of 
NaV1.7, effective drug development remains a challenge, particularly in translating basic 
discoveries into clinical advances. Here, we echo statements made in Foadi’s review [25] in 
highlighting issues with promiscuity of drugs targeting NaV1.7. While several examples of 
drugs inhibiting NaV1.7 exist, they also engage other mechanisms of action rendering them 
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susceptible to unwanted side effects. Compounds that affect NaV1.4 or NaV1.5 can produce 
side effect on motor control and heart rhythm whereas compounds that affect NaV1.1–1.3 
can produce CNS side effects on consciousness [24]. Additionally, while several compounds 
have been characterized due to their antinociceptive promise based on chemical structural 
analysis, these sodium channel inhibitors have failed to produce similar analgesic effects in 
clinical studies [26].
Xenon and Convergence have moved into clinical trials with chemotypes based on a neutral 
spiro-oxindole group and a weakly basic proline respectively [24]. Specifically, Xenon’s 
Xen907 was derived from a series of structural optimizations initially based on a 3-
hydroxyoxindole analogue [27]. From here, the furyl moiety was replaced with a thienyl 
ring and the β-hydroxyketone was altered by shortening of the methylene spacer to afford a 
3-aryl-3-hydroxyoxindole. From this base structure, a series of additional changes were 
introduced including addition of grignard reagent to afford a diol and triethylsilane-mediated 
dihydroxylation to make a phenol derivative. Aldol condensation and finally intramolecular 
cyclization resulted in spiroether Xen907. Convergence’s CNV1014802 initially based on a 
weakly basic proline was altered based on a patented process of alpha-carboxamide 
pyrrolidine derivatives arriving its current structural form.
AstraZenaca has reportedly obtained several patents covering a diverse chemical series 
including chromane with effects on NaV1.7, but also other Nav1.x channels. Merck’s 
benzazepinone has shown action on NaV1.7, NaV1.8, and NaV1.5. Pfizer and Icagen in 
collaboration have published several patents based on acidic and zwitterionic series, 
including several compounds with efficacy on NaV1.7 channels and one molecule currently 
in clinical trials [24]. Amgen has described a novel series of compounds, triazine derivatives 
that are NaV1.7 modulators [23]. Specifically of these, positive results have been shown in 
Phase II clinical trials for Xenon’s XEN402 in topically reducing postherpetic neuralgia and 
orally for primary erythromelalgia [28]. Pfizer had previously advanced a NaV1.7-
interacting compound, PF-05089771 into phase II clinical trials for treating pain from 
diabetic peripheral neuropathy [29]. In its current complete status after analyzing the data of 
141 participants, it appears that participants treated with the Pfizer compound had in average 
lower weekly pain scores in comparison to those treated with pregabalin or placebo. 
However, other measured outcomes including prevalence of neuropathic pain symptoms 
such as burning and tingling as well as ratings of overall improvement status remained 
insignificantly different. Convergence’s CNV1014802 has shown modest positive results for 
treatment of trigeminal neuralgia [30]. However, recent data has shown the Convergence 
compound, now renamed as raxatrigine to be non-selective NaV inhibitor, exhibiting action 
not only on NaV1.7, but also NaV1.3 [31]. Despite promising results, isoform selectivity and 
biophysical characteristics of many of these compounds remain to be disclosed.
Along similar lines, Genentech reported on a series of aryl sulfonamide inhibitors potentially 
blocking human NaV1.7 by engaging voltage sensor domain four in its activated 
conformation [32]. Functional studies using patch-clamp electrophysiology demonstrated 
isoform-selective high affinity binding; however, the pain blocking potential/relevancy or 
clinical development status of these molecules is unknown. Finally, Payandeh and Hackos 
[33] suggest three NaV1.7 binding sites that might offer the highest potential for discovery 
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and optimization of NaV1.7-selective inhibitors. However, the use of these three 
extracellular druggable sites remains to be adequately exploited. These strategies inevitably 
begin to cater to the need for better specific therapies by targeting NaV1.7 without 
modifying other NaV-family channels and may offer promise for future clinically available 
NaV1.7-selective drugs.
3. Transcriptional silencing of NaV1.7 – taming the beast from within
In studying transcriptional and post-transcriptional mechanisms that regulate SCN9A, Cox 
and colleagues discovered a unique mechanism for inhibiting NaV1.7 activity [34]: a natural 
antisense transcript (NAT) for SCN9A. Remarkably, overexpression of the NAT, in vitro 
specifically, decreased the level of mRNA, protein and peak current of NaV1.7. As the NAT 
is conserved in the NaV1.7 gene from rodents to humans, the authors postulated that the 
NAT may play an important role in regulating human pain thresholds and may represent a 
potential candidate gene for individuals with chronic pain. Surprisingly, however, mRNA 
levels of NAT and SCN9A were not increased in models of inflammatory pain [34], despite 
previous demonstration of elevated NaV1.7 protein levels following injections of 
inflammatory agents [35]. The discordance in these results may be explained by the 
demonstration that NAT expression is non-detectable in DRGs where there is robust Scn9a 
expression and conversely, in the only neuronal subtype without Scn9a expression – the 
large proprioceptor DRGs, there is relatively high expression of the NAT; the DRGs were 
divided into 11 categories based on single-cell RNA sequencing [36]. As summarized by 
Koenig, the human NAT has a number of single nucleotide polymorphisms (SNP) linked to 
SCN9A related pain disorders, including three mutations linked to primary erythromelalgia 
(PE) (A863P, V872G, Q875E), two SNPs linked to congenital insensitivity to pain (CIP) 
(R896Q, W897X), five mutations linked to CIP (R1599X), PE (A1632T) and PEPD 
(L1612P) as well as an overlapping phenotype (A1632E) ([37] and references therein). 
These SCN9A point mutations previously shown to cause the human monogenic pain 
disorders CIP, IEM, and PEPD result in a change in the sequence of the NAT, implying that 
loss of function mutations in the NAT may be responsible for inherited painful disorders 
linked to mutations in NaV1.7. As another NAT for the voltage-dependent potassium channel 
Kcna2 has been reported to be upregulated in response to peripheral nerve injury [38], 
targeting NATs may represent a new opportunity for designing NaV1.7 therapeutics for pain.
Muroi and colleagues demonstrated the efficacy of adeno-associated virus-based delivery of 
short hairpin RNA against NaV1.7 silencing excitability in sensory neurons of guinea pigs 
[39], Cai and co-workers also used a lentiviral-based knockdown of NaV1.7 in Lumbar 5 
DRGs to attenuate burn-injury induced mechanical allodynia and thermal hyperalgesia in 
rats [40], and Fink and others reported the efficacy of non-replicating herpes simplex virus 
vector-mediated microRNA (miRNA) in reducing cold allodynia, thermal hyperalgesia, and 
mechanical hyperalgesia in rats with painful diabetic neuropathy [41]. The same group also 
reported a role for GABA acting through the GABAB receptor (Gi/o) on decreasing NaV1.7 
levels which may account for why spinal release of GABA (due to DRG neurons 
overexpressing a GAD expressing vector) reduces pain related behaviors in rats with 
peripheral diabetic neuropathy [42]. But beyond these reports, silencing of NaV1.7 has not 
been tried in the clinic.
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Evidence also suggests that alternative splicing of exons 5 and 11 regulates NaV1.7 
expression. Four alternative splice variants are expressed in human DRG neurons, two of 
which differ in exon 5 by two amino acids in the S3 segment of domain I (exons 5A and 
5N). Two others differ in exon 11 by the presence (11L) or absence (11S) of an 11 amino 
acid sequence in the loop between domains I and II, an important region for protein kinase A 
(PKA) regulation. Expression of different splice variants can alter NaV1.7 channel kinetics. 
After injury, an ‘11S’ variant that lacks 11 amino acids undergoes disproportionate 
upregulation compared to other variants. PKA phosphorylation of the 11S variant produces a 
hyper-polarizing shift in NaV1.7 activation, which not only promotes DRG hyperexcitability, 
but forms part of the response mechanism that upregulates NaV1.7 following an injury [43]. 
Targeting the splicing machinery may be an opportunity to develop therapeutics with the 
ideal of favoring proportions of the alternative splice variants towards those facilitating 
suppression of generation of action potentials, thus contributing to prevention of neuropathic 
pain.
4. NaV1.7 and opioid signaling – the missing link?
Increasing evidence also mandates attention to pain mechanisms mediated by the complete 
absence or strong inhibition of NaV1.7 activity. Direct analgesic contributions of 
endogenous opioid signaling in the absence of NaV1.7 represent one such avenue of interest 
[44–46]. Until now, most therapeutic strategies have held a narrow scope of targets, 
centering on only voltage-gated sodium channels or opioid receptors. Some evidence 
suggests that shifting the focus to opioid signaling apart from the receptor may yield more 
promising answers, although this view remains contested and some researchers continue to 
assert that targeting NaV1.7 is sufficient in the battle against chronic pain
Examination of endogenous opioids in the DRGs of NaV1.7-null mutant mice revealed 
upregulation of both Proenkephalin (Penk) mRNA and its downstream protein products in 
primary afferent sensory neurons [44]. Furthermore, these NaV1.7-null mutant mice 
exhibited significantly enhanced met-enkephalin immunoreactivity (over twofold increase) 
compared to wildtype littermates [44]. The enhanced expression of endogenous opioids is 
correlated to intracellular sodium concentrations such that the loss of NaV1.7 activity 
promotes opioid production and these opioids act can act on inhibitory G-protein coupled 
receptors and prevent sensory neuron firing [44]. Interestingly, this phenomenon linking 
voltage-gated sodium channel and endogenous opioid expression appears constrained to 
TTX-sensitive sodium channels. Parallel investigation of DRGs in Nav1.8-null mutant mice 
did not reveal changes in Penk mRNA [44]. A complementary analysis of Penk expression 
in wildtype DRGs with pharmacologically inhibited TTX-sensitive sodium channel activity 
revealed similar results and augmented Penk expression [44]. By contrast, introducing the 
ionophore monensin to increase intracellular sodium levels in wildtype mouse DRGs elicited 
the opposite effect; this led to Penk mRNA downregulation while the housekeeping gene 
Gapdh remained unchanged [44]. These findings reinforce a substantial molecular role for 
Penk-associated protein products’ promotion of analgesia in the absence of NaV1.7 activity.
Additional studies support an interaction of NaV1.7 activity and endogenous opioid-
dependent pain signaling. In conditional knockout mice with NaV1.7-deficient DRGs, 
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naloxone administration dramatically reversed analgesia and re-established nociception to 
levels comparable to littermate controls in both the Hargreaves and Randall-Sellitto tests for 
thermal and noxious mechanical pain, respectively [44]. Notably, both male and female 
NaV1.7-deficient mutants demonstrated this trait. This provided the first evidence for 
translation of endogenous opioid-dependent pain signaling to the behavioral level.
Building on these initial results, investigation of nociceptive behaviors in NaV1.7-null 
mutants with additional global deletions of μ-opioid receptors (MORs) and δ-opioid 
receptors (DORs) followed. Mutants deficient in both MORs and NaV1.7 regained minimal 
nociceptive response to acute heat, but naloxone administration nearly restored their 
nociceptive response to wildtype levels [46]. This demonstrates that MORs alone cannot 
account for opioid-dependent analgesia in the absence of NaV1.7. Studying mutants 
deficient in both DORs and NaV1.7 in parallel revealed similar results, indicating that DORs 
alone cannot account for opioid-dependent analgesia in the absence of NaV1.7 [46]. 
Applying the potent selective MOR antagonist CTOP to DOR/NaV1.7-null mutants resulted 
in an equivalent elimination of the analgesic phenotype compared to naloxone 
administration to this mutant [46]. Mutants deficient in NaV1.7, MOR, and DOR 
recapitulated this loss of analgesia, yet, administration of the κ-opioid receptor (KOR) 
antagonist norbinaltorphimine (norBNI), did not further alter the nociceptive response [46]. 
Altogether, these data suggest that opioid-dependent analgesia in the absence of NaV1.7 
function relies on both MOR and DOR, but not KOR, signaling.
Delving into potential molecular links between NaV1.7 and opioid-associated DNA 
elements, the transcription factor Nuclear Factor of Activated T Cells 5 (Nfat5) was 
identified, with five consensus binding sites upstream of the Penk coding region. Previous 
work established the regulation of Nfat5 activity by NaV1.7 and intracellular sodium levels 
[46]. In experiments examining the effects of intracellular sodium changes, monensin 
administration decreased Nfat5 mRNA, while TTX administration increased Nfat5 mRNA—
in addition to these treatments’ corresponding effects on Penk mRNA [46]. These results 
point to indirect transcriptional control of Penk through intracellular sodium-mediated Nfat5 
regulation (Figure 2) [46]. TTX-mediated elevation of Nfat5 mRNA was absent in NaV1.7-
deficient mice, implying that NaV1.7 is the locus of action for this mechanism of 
endogenous opioid production. Furthermore, Penk mRNA expression was increased in 
Nfat5-deficient mice, and even more so in mutants deficient in both NaV1.7 and Nfat5 [46]. 
Yet, Nfat5-deficient mice developed normal noxious mechanosensation and 
thermosensation, despite the augmented Penk mRNA expression [46]. These results suggest 
that loss of NaV1.7 has downstream effects on Nfat5 and Penk which are required events to 
achieve NaV1.7-targeted analgesia. As a result, therapeutic strategies which target the 
channel may also need to control Nfat5 and Penk in order to phenocopy Na 1.7-mediated 
reduction of pain in preclinical models.
At the same time, attempts to replicate some of the previously discussed work have led to 
contradicting results—particularly in the case of those scrutinizing effects of MOR and 
DOR-associated endogenous opioid peptide enkephalins on pain phenotypes [47]. In a 
parallel study within a tamoxifen-inducible NaV1.7 conditional knockout mouse, data 
revealed similar patterns of Penk mRNA expression alteration, but without naloxone-
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mediated induction of normal pain thresholds [47]. As a result of these reports, opioid-
dependent analgesic mechanisms contributing to electrical signaling or intracellular sodium 
concentrations, in the absence of NaV1.7, remain controversial and disputed.
Even so, it remains clear that NaV1.7 plays a critical role in pain signaling, despite the 
complexity of molecular partners that help coordinate its downstream activity. Specifically, 
observation of altered Penk mRNA expression, in response to a NaV1.7-mediated 
intracellular sodium gradient, further ties NaV1.7 and endogenous opioid signaling together. 
NaV1.7 also contributes to maintenance of a delicate pro- and anti-nociceptive balance. 
Disruption of this balance, as in the case of NaV1.7 knockout mice that simultaneously 
exhibit 5-Hydroxytryptamine receptor 4 (5-HT4) downregulation and inhibited 
pronociceptive serotonergic signaling, accompanies aforementioned increases in endogenous 
opioid levels [48]. Given this, the intertwined fates of NaV1.7 and endogenous opioids in the 
intracellular landscape of nociceptive regulation ought to guide the scope of future 
therapeutic strategies. While current approaches may fail to harness this link for augmented 
benefit in the realm of drug discovery, accounting for the greater NaV1.7 interactome will 
likely yield a more potent analgesic.
5. The interactome of NaV1.7 – the tail wagging the dog
The identification of NaV1.7 as a molecular target in the battle against chronic pain has been 
a key milestone. Subsequent efforts to produce clinically adequate NaV1.7 inhibitors have 
become more specific to the channel and more successful over time, but side effects and 
specificity still remain significant obstacles. Complexity of the NaV1.7 interactome further 
increases the difficulty of designing a small molecule inhibitor with the ideal antinociceptive 
profile. The successful development of both safe and efficacious NaV1.7 inhibitors could 
benefit from targeting the channels endogenous modifiers. By generating a mouse wherein 
NaV1.7 is tagged to exogenous protein epitopes that are targets of high-affinity antibodies, 
purification of the channel together with its interacting partners has recently become 
possible. Importantly, isolated recordings of tagged NaV1.7 channels and expression of the 
channels in mice produce wildtype current properties and pain expression [49]. Considering 
the wide breadth of NaV1.7-interacting partners John Wood and has group have identified by 
this technique [49], here we consider those proteins already implicated in antinociception of 
particular interest, or ones with the capacity to further augment an inhibitor’s functional 
scope (Figure 1).
(A) Homer2
Among the NaV1.7 interactome, the post-synaptic density scaffolding protein Homer2 
represents one such interacting partner that also mediates NMDAR signaling, especially in 
the dorsal horn of the spinal cord [50]. Homer is ubiquitously expressed including in both 
peptidergic and non-peptidergic DRG neurons and in the spinal cord, in particular in the 
spinal inhibitory neurons transmitting GABA and/or glycine as well as excitatory 
glutamatergic neurons. Various isoforms of Homer are expressed in different tissues and 
other Homer isoforms may also facilitate its nociceptive functions. If interaction between 
Homer proteins and NaV1.7 stabilize excitatory NMDAR signaling, then this excitatory 
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signaling could be the first step of a feed-forward process that culminates in NaV1.7 gating 
and an increase in DRG sensitivity. Evidence indicates that both Homer1b/c and Homer2a/b 
expression coincidentally increase alongside mGluR5 and GluN2A/B levels in a chronic 
constriction injury (CCI) model of neuropathic pain [51]. Notably, CCI elicited long-lasting 
increases in Homer1b/c and Homer2a/b expression within the postsynaptic density of dorsal 
horn spinal cord neurons in addition to supraspinal structures associated with the cognition 
of pain—especially the prefrontal cortex and thalamus [51]. This, in parallel with CCI-
induced nociceptive behaviors, intimates a role for Homer1b/c and Homer2a/b expression in 
facilitating nociception. Further support can be derived from exacerbation of CCI-induced 
mechanical and cold hypersensitivity in a model exhibiting virus-mediated overexpression of 
Homer1c and Homer 2b, although mutants deficient in both Homer1 and Homer2 
demonstrated no significant change in nociceptive capacity [51].
(B) Phosphatidylethanolamine-binding protein 1 (PEBP1)
Considering the significance of opioid-dependent signaling mechanisms in analgesia when 
NaV1.7 expression is absent, phosphatidylethanolamine-binding protein (PEBP1, 
alternatively named Raf-1 kinase inhibitor protein or RKIP) is of interest as an endogenous 
morphine-6-glucuronide-binding (M6G) protein [52]. It is most highly expressed in thyroid 
and parathyroid glands, adrenal glands, liver, kidney, and testis. There is medium expression 
in cerebral cortex, hippocampus, caudate, cerebellum. It is also expressed in central canal 
neurons (GABA), inhibitory neurons of the spinal cord (GABA, Glycine), and excitatory 
neurons of the spinal cord (Glutamate). There is high expression in peptidergic 
(neurofilament-positive) DRG neurons, but even higher expression in non-peptidergic DRG 
neurons. Though there is not much differential developmental expression of PEBP1, there 
seems to be higher expression of the protein in very aged mice. Data from a bovine 
chromaffin cell model also show PEBP1 is not only highly resistant to proteolytic 
degradation, but that PEBP1 binding to M6G functionally acts as a protected molecular 
vehicle for intracellular transport [52]. However, PEBP1 does not appear to play a role in 
known mechanisms for MOR-mediated regulation of extracellular signal-regulated kinase 
signaling [53]. While PEBP1 exhibits direct binding to M6G but not morphine, PEBP1 
appears to limit overall morphine metabolism and potentiates the opioid’s antinociceptive 
properties [54]. Targeting this regulator of intracellular Raf-1 kinase signaling could 
therefore be utilized to enhance opioid potency and reduce the dose required to achieve 
analgesia.
(C) Fatty acid binding protein 7 (FABP7)
As one amongst a family of cytosolic proteins implicated in lipid transport, FABP7 is known 
to bind N-acylethanolamines (NAEs), such as the endocannabinoid anandamide, which 
plays an acknowledged role in antinociception through an association with cannabinoid 
receptors [55]. FABP7 is largely detected in tissues of the cerebral cortex, hippocampus, 
caudate, and cerebellum. It is not detected in neurons of the spinal cord, and lowly, but 
equally in non-peptidergic, neurofilament-positive, and peptidergic neurons. While fatty acid 
amine hydrolases (FAAHs) and FABPs facilitate NAE catabolism, inhibition of FAAHs and 
FABPs potentiates NAE signaling to produce anti-inflammatory and antinociceptive effects 
amongst models of inflammatory, visceral, and neuropathic pain through effects on 
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cannabinoid receptor 1 (CB1), cannabinoid receptor 2 (CB2), and PPARα [56, 57]. If 
interaction between FABP7 and NaV1.7 promotes FABP7 activity, then targeting this 
interaction could curb pain. It follows that pharmacological inhibition of FABP7 in both 
formalin and carrageenan models of inflammatory pain reduced nociceptive behaviors, 
alongside parallel results in an acetic acid model of visceral pain [58, 59]. However, only 
relief from thermal, but not mechanical, hyperalgesia was attained by this inhibition in 
models of neuropathic pain [59]. In the same inflammatory models of pain, administration of 
CB1 and PPARα antagonists prior to treatment with FABP inhibitors yielded no indication 
of analgesia; mice continued to exhibit nociceptive behaviors (both thermal and mechanical 
hyperalgesia), suggesting that FABP-mediated antinociception harnesses CB1 and PPARα 
activity [59]. Interestingly enough, naloxone administration failed to counteract these 
antagonists, implying that opioid receptors do not play a role in FABP inhibitors’ 
antinociceptive mechanism of action [59].
(D) Mitogen-activated protein (MAP) kinases
Serine/threonine-specific MAP kinases typically link membrane receptor activation to 
cytosolic signaling cascades [60]. MAP kinases are expressed in all tissues, with high 
expression in tissues of the cerebral cortex, adrenal gland, appendix, skeletal muscle, lung, 
bronchus, liver, gallbladder, pancreas, stomach, duodenum, colon, rectum, kidney, urinary 
bladder, testis, prostate, seminal vesicle, vagina, and placenta. They are also expressed in 
central canal neurons, excitatory, and more prevalently in inhibitory neurons of the spinal 
cord. In DRGs, MAP kinases are expressed in neurofilament-positive neurons, as well as in 
peptidergic and non-peptidergic neurons. In nerve ligation animal models of neuropathic 
pain, inhibition of ERK, p38, and JNK MAP kinases relieved mechanical allodynia, while 
p38 inhibition specifically reversed thermal hyperalgesia [61]. Coincident upregulation of 
p38 and ERK1/2 MAP kinases along with NaV1.3, NaV1.7, and NaV1.8 in painful human 
neuromas provide additional support and a potential mechanism for MAP kinase-mediated 
nociception [62]. Interestingly, phosphorylation of NaV1.8 by p38 increases peak current 
density in DRGs and suggests p38 contributions to not only inflammatory, but neuropathic 
pain [63]. In models of chronic pain where NaV1.7 expression is increased [64], MAP kinase 
enhancement of allodynia might be NaV1.7-trafficking dependent.
(E) Filamin A
The actin-binding protein filamin A crosslinks actin filaments while participating in 
cytoskeleton remodeling to rearrange and anchor membrane proteins [65]. Filamin A is 
expressed in tissues of the bone marrow, smooth muscle, lung, kidney, endometrium, ovary, 
and placenta. At low levels, it is also expressed in all subtypes of neurons of the spinal cord, 
and similarly at low levels in all DRG neuronal subtypes. Filamin A is known to play a role 
in the skeletal and brain development, as it is involved in building the extensive extracellular 
matrix. This is supported by a reduction in protein levels in the adult brain. In addition to 
these functions, filamin A is required for MOR-mediated activation of the MAP kinase p38, 
and deletion studies indicate that filamin A’s MOR-binding site resides on its 24th repeat, 
near its C-terminal [66]. While the N-terminal of filamin A supports its actin-binding 
functions, absence of this domain did not obstruct other MOR-associated activity [66]. In the 
complete absence of filamin A, however, MOR-agonist administration led to a marked 
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upregulation of MOR expression [66, 67]. By contrast, high-affinity binding of naloxone to 
filamin A appeared to prevent MOR-dependent opioid tolerance and dependence, according 
to measurements of Gs coupling and cAMP [68]. Future studies to clarify filamin A-
mediated regulation of MOR and to maximize its therapeutic utility are undoubtedly 
necessary and the extent to which NaV1.7 binding contributes to filamin A activity is of 
particular interest.
(F) Microtubule-associated protein 2 (MAP2)
MAP2 belongs to the microtubule-associated protein family and functions in both promoting 
and stabilizing microtubule assembly [69]. MAP2 is expressed highly in tissues of the 
cerebral cortex, hippocampus, caudate, and cerebellum, and low levels in the pancreas and 
colon. Though it is expressed in all spinal cord neuronal subtypes, it is more largely 
expressed in the inhibitory GABA-ergic and glycinergic neurons. In DRGs, while expressed 
in all neuronal subtypes, it is mostly expressed in neurofilament-positive neurons. 
Developmentally, higher molecular weight isoforms of MAP2 increase in expression with 
age. These isoforms of MAP2 also play a role in neuronal cell survival during cell stress. Its 
enrichment in dendrites implies a role in neuronal development through these morphological 
structures [69]. In a CCI-induced model of neuropathic pain, rat DRGs exhibited marked 
downregulation in MAP2 expression, especially at the site of injury [70]. Co-localization of 
calcium-calmodulin protein kinase II alpha (CaMKIIα) and MAP2 alongside coincident 
modulation of their expression within the trigeminal subnucleus caudalis in an inferior 
alveolar nerve transection model of neuropathic pain reinforce MAP2’s role in the context of 
pain signaling [71]. Known functions of MAP2 in tubulin binding also provide a link to the 
collapsin response mediator family of cytosolic proteins, with more recently described roles 
in the regulation of voltage gated calcium and sodium channel trafficking [72–74]. The 
aforementioned shifts in expression within models of neuropathic pain ideally position 
MAP2 for coordinating a nociceptive response within dendrites. Given coincident 
expression of MAP2, sodium channels, and calcium channels, it is possible that these 
channels’ expression is linked to MAP2 expression in a directly proportional manner. This 
theory would suggest that therapeutic approaches limiting MAP2 expression or signaling 
would proportionally reduce sodium or calcium channel-mediated pain signaling, while 
potentially facilitating analgesia. The downregulation of MAP2 in CCI-induced neuropathic 
pain, however, suggests the opposite; MAP2 upregulation may, in fact, prove more beneficial 
in limiting nociception. From the existing body of knowledge on neuropathic pain, it 
remains unclear which is a more probable role for MAP2. Further investigation is necessary 
to clarify this relationship.
(G) E3 ubiquitin ligase Nedd4–2
Neural precursor cell expressed developmentally down-regulated protein 4 (Nedd4–2) 
belongs to the HECT ubiquitin ligases that function in the ubiquitin proteasome system of 
protein degradation. The encoded protein contains an N-terminal calcium and phospholipid 
binding C2 domain followed by multiple tryptophan-rich WW domains and, a C-terminal 
HECT ubiquitin ligase catalytic domain. It plays a critical role in the regulation of a number 
of membrane receptors, endocytic machinery components and the tumor suppressor PTEN. 
Nedd4–2 is highly expressed in tissues of the cerebral cortex, thyroid gland, appendix, 
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bronchus, gallbladder, pancreas, stomach, duodenum, small intestine, colon, rectum, kidney, 
prostate, seminal vesicle, fallopian tube, cervix, endometrium, and placenta. It is expressed 
in the spinal cord neurons at low levels, but at very high levels in peptidergic and non-
peptidergic neurons. It has diminished expression in neurofilament-positive neurons. With 
regard to development, it is necessary for development of the heart, and additionally for 
neuronal development and homeostasis in the brain. Nedd4–2 monoubiquitinates NaV1.7 to 
promote channel endocytosis, especially in sensory neurons [64]. Evidence clearly indicates 
that Nedd4–2 modulates not only NaV1.7 channel expression, but current density and 
neuronal excitability. It follows that virus-mediated overexpression of Nedd4–2 attenuates 
NaV1.7 expression and current density, contributing to alleviation of mechanical allodynia in 
model of neuropathic pain [64]. In addition to the endocytic protein Numb and epidermal 
growth factor receptor pathway substrate 15 (Eps15), Nedd4–2 also appears to be a requisite 
participant in NaV1.7’s clathrin-mediated internalization [73]. Specificity of Nedd4–2-
mediated NaV1.7 internalization, however, depends on the implication of other cytosolic 
proteins within the internalization complex—especially collapsin response mediator protein 
(CRMP2) (see below) [73, 75, 76]. Through modulation of NaV1.7 surface expression, 
Nedd4–2 indirectly attenuates pain signaling in sensory neurons.
(H) Calretinin
A calcium binding protein involved in calcium signaling and buffering, calretinin (CR) has a 
demonstrated role in modulation of neuronal excitability and induction of long-term 
potentiation [77, 78]. CR is highly expressed in tissues of the cerebral cortex, hippocampus, 
caudate, cerebellum, adrenal gland, testis, and soft tissue. It is expressed, at discernable 
levels, in inhibitory neurons of the spinal cord and there is very low expression in 
neurofilament-positive DRG neurons. In the superficial dorsal horn of the spinal cord, CR-
expressing neurons have been implicated in processing nociceptive, thermal, itch, and light 
touch sensations [79]. In early development calretinin may be involved in regulating 
neuronal migration. “Typical” CR neurons comprise ~85% of total CR-expressing 
population and behave like excitatory interneurons, with delayed firing discharge and large 
rapid A-type potassium currents. By contrast, “atypical” CR-expressing neurons comprise 
the remaining 15% and exhibit traits characteristic of inhibitory interneurons, including 
tonic firing, initial bursting discharge, Ih currents, and islet cell morphology [79]. Some 
evidence suggests that the TRPV1-mediated nociceptive response (especially in cases of 
overstimulation) relies on a calretinin-dependent calcium buffering to protect CR-expressing 
DRGs from triggering apoptotic mechanisms [80]. It remains unclear, however, whether 
nociceptive responses mediated by TRPV1, and other pain-associated channels or receptors, 
require CR-expression. In certain pain phenotypes, enhancement of these calretinin-
dependent neuroprotective mechanisms may also serve antinociceptive function by limiting 
localized calcium signaling near NaV1.7 channels immediately following glutamatergic 
receptor activation.
(I) Neurotrimin
A member of the IgLON immunoglobulin superfamily, neurotrimin is homologous to 
opioid-binding cell adhesion molecule (OBCAM) [81]. Neurotrimin is most highly 
expressed in the cerebellum, but also in lower levels in tissues of the cerebral cortex, lung, 
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hippocampus, caudate, soft tissue, and skin. It is expressed equally in all spinal cord 
neuronal subtypes. In DRGs, neurotrimin is mostly expressed TRPM8-expressing 
peptidergic neurons and a subset of glutamatergic neurofilament-positive neurons. 
Developmentally, neurotrimin expression migrates from initial expression on un-myelinated 
axons to largely being at excitatory synaptic contact sites, suggesting a role in 
synaptogenesis. While very little is known about the pain-associated functions of 
neurotrimin, OBCAM overexpression in astrocytes has been reported to increase cell size 
and proliferation through a fibroblast growth factor 2 receptor-mediated pathway [82]. 
Additional studies are necessary to determine the role of both cell adhesion molecules in 
pain. Immediately relevant to OBCAM interaction with NaV1.7 is whether binding with the 
channel modifies endogenous opioid signaling.
(J) Neurofascin
With multiple IGcam and fibronectin domains, neurofascin is an L1 family immunoglobulin 
cell adhesion molecule that localizes to the axon initial segment (AIS) and nodes of Ranvier 
[83]. Neurofascin is mostly expressed in tissues of the cerebral cortex and cerebellum. 
Neurofascin is lowly expressed, if at all, in all neuronal spinal cord subtypes. In DRGs, this 
protein is mostly expressed in neurofilament-positive neurons. Developmentally, embryonic 
DRGs mostly express neurofascin with one of the two following domains: a mucin-like 
domain and a fifth fibronectin type III repeat. Just prior to birth neurofascin proteins co-
express the domains. Its expression in the peripheral nervous system posits a role for it in 
modulating adhesive interactions of DRG neurons with Schwann cells. Notably, high 
densities of voltage-gated sodium channels cluster at both the AIS and nodes of Ranvier, 
sites enriched with neurofascin. Unsurprisingly, evidence indicates that sodium channel beta 
(β) 1 and β3 subunits associate with neurofascin through their extracellular 
immunoglobulin-like domains [84]. In HEK293 cells, β1 and β3 upregulated heterologously 
expressed NaV1.7 channels [64]. Given the known role of β proteins in channel kinetics, 
biosynthesis, trafficking, sub-cellular localization, and cell adhesion, there is also potential 
for neurofascin to facilitate these functions—all of which are critical in modulating the 
nociceptive response in neurons. Inhibition of neurofascin, alongside β subunits, to 
indirectly reduce NaV1.7 surface expression may be valuable.
(K) Fibroblast growth factor 13 (FGF13
Intracellular fibroblast growth factors (FGFs) are not yet well understood but are found in 
the nervous system [85]. FGF13 is expressed in a small subset of inhibitory GABA-ergic 
and glycinergic spinal cord neurons as well as a subset of excitatory glutamatergic spinal 
cord neurons. In DRGs, FGF13 is expressed largely in peptidergic and non-peptidergic DRG 
neurons, with very low levels being found in neurofilament-positive DRG neurons. FGF13 
plays a role in neuroblast polarization and migration in the cerebral cortex and hippocampus. 
Expression of FGF13 is markedly reduced in the adult brain, with transient expression in 
cortical neurons during brain development. DRGs maintain high levels of FGF13 expression 
from development through adulthood [85, 86]. Interestingly, loss of FGF13 in mouse DRGs 
selectively abolishes heat nociception and prevents sustained action potential firing [87]. 
Furthermore, FGF13 directly interacts with the C-terminus of NaV1.7, increasing NaV1.7 
current density without altering its activation/inactivation properties and maintaining its 
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surface expression during noxious heat stimulation [87]. Disruption of this interaction 
reduced heat-evoked action potentials and nociceptive behaviors, marking the FGF13/
NaV1.7 complex as a robust target for treating thermal hypersensitivity [87].
(L) Multiple PDZ domain protein (MPDZ) and PDZD2
MPDZ and PDZ2 are present at medium to low expression in all tissues. The proteins are 
discernably expressed in GABA-ergic central canal spinal cord neurons. In DRGs, this 
protein is expressed in all DRG neuronal subtypes but more so in peptidergic and non-
peptidergic neurons and less so in neurofilament-positive DRG neurons. The MPDZ is 
primarily expressed in synapses and tight junctions [88]. There, it colocalizes with the 
scaffolding protein PSD95, and both are thought to be implicated in opioid tolerance and 
opioid-induced hyperalgesia [89]. Most significantly, heterozygous MPDZ+/− mice 
exhibited reductions in both of these traits. PDZD2 (PDZ-domain 2 protein) shares some 
structural traits with MPDZ and was found to bind directly to the intracellular loops of 
NaV1.8 and NaV1.7 [90]. Interestingly, PDZD2-deficient mice do not exhibit significantly 
altered nociceptive responses [90]. The precise role of PDZD2-binding to NaV1.7 and 
NaV1.8 requires further exploration. Therapeutic approaches centering on both MPDZ and 
PDZD2 may alleviate opioid-induced hyperalgesia while potentially impacting sodium 
channel surface expression. By targeting NaV1.7 expression specifically within postsynaptic 
densities, threshold current generation by the channel could be severely blunted by only 
subtle reduction of total NaV1.7 protein surface expression.
(M) β subunits
The beta subunits are arguably the best-understood accessory proteins of NaV channels and 
have been extensively described in several reviews [91–93]. They are expressed in excitable 
cells of the CNS, PNS, heart and skeletal muscle and are also expressed in non-excitable 
cells, including astrocytes and radial glia, vascular endothelial cells, and cancer cells. 
Developmental differences also exist in their expression with β1B and β3 being highly 
expressed prenatally with decreasing abundance after birth, whereas β1 and β2 expression 
increases during postnatal development and remains high in adulthood; the developmental 
time course of β4 expression is unknown, but it is expressed postnatally in rat. In 2013, 
Laedermann and colleagues showed that the NaV1.7 accessory subunits β1 and β3, but not 
β2 or β4 associate with NaV1.7 in the ER/Golgi and mediate from there the channels’ 
glycosylation state and membrane expression [94]. Cell-cell interactions and subcellular 
localization can be mediated by the extracellular domain of β subunits, which contain 
immunoglobulin-like domains that resemble other families of adhesion molecules. The 
NaV1.7 accessory protein β2 plays an important role in channel forward trafficking shown 
by β2-null mice that display reduced NaV1.7 protein expression, decreased TTX-S current 
densities, and decreased thermal and inflammatory pain thresholds [95]. Koenig and 
colleagues also identified the β3 subunit in their tandem affinity purified proteomics data 
and verified the binding to NaV1.7 with reciprocal coimmunoprecipitations from DRG and 
olfactory bulb [49]. Despite the knowledge of the functional modification of NaV1.7 
accessory by β subunits [92, 93], these auxiliary subunits have not been targeted for 
allosteric regulation.
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(N) Collapsin response mediator protein 2 (CRMP2)
Classical roles for CRMP2 include promotion of neurite outgrowth, neuronal polarization, 
progenitor proliferation, radial migration and microtubule network assembly (see review 
[96]). CRMP2 is expressed mainly in the nervous system as inferred from positive 
immunoblotting signals from brain and DRG homogenates while no expression was detected 
in intestine, lung, liver, kidney, heart, muscle or any other tissues from chicken. Our work 
has demonstrated CRMP2 to be a major hub for the trafficking of voltage-gated calcium and 
sodium channels in pain signaling [74, 97–99]. We identified a novel trafficking platform for 
NaV1.7 driven by hierarchical interactions with post-translationally modified versions of the 
binding partner CRMP2 [73]; a finding confirmed by the Wood group [49]. The novel 
binding described between CRMP2 and NaV1.7 was enhanced by conjugation of CRMP2 
with small ubiquitin-like modifier (SUMO), and further controlled by the phosphorylation 
status of CRMP2. We reported that CRMP2 SUMOylation is enhanced by prior 
phosphorylation by Cdk5 at serine-522 and antagonized by the Src family kinase Fyn 
phosphorylation at tyrosine-32 [73]. As a result of CRMP2 loss of SUMOylation and 
binding to NaV1.7, the channel displayed decreased membrane localization and current 
density, and a commensurate reduction in neuronal excitability. Preventing CRMP2 
SUMOylation with a SUMO-impaired CRMP2-K374A mutant triggered NaV1.7 
internalization in a clathrin-dependent manner involving the E3 ubiquitin ligase Nedd4–2 
and endocytosis adaptor proteins Numb and Eps15 (Figure 3A)[72, 73, 75, 100]. Notably, 
CRMP2 SUMOylation is increased in neuropathic pain and drives nociceptive behaviors 
(Figure 3B) via increased NaV1.7 synaptic localization in the dorsal horn of the spinal cord 
or increased NaV1.7 insertion along the central terminal projection [72]. Using rational 
design, we identified a heptamer peptide containing the CRMP2 SUMOylation consensus 
site fused to the transduction domain of the HIV-1 tat protein, called t-CSM, to disrupt the 
CRMP2-Ubc9 interaction (Figure 3C). This t-CSM peptide inhibited CRMP2 SUMOylation, 
NaV1.7 membrane trafficking, and specifically inhibited NaV1.7 sodium influx in sensory 
neurons [76]. Intrathecal injection of t-CSM reversed nerve injury-induced thermal and 
mechanical hypersensitivity with no sedation or motor impairment in rats [76]. Structural 
modeling has led to the identification of a pocket harboring CRMP2’s SUMOylation motif 
that, when targeted through computational screening of ligands/molecules, is expected to 
identify small molecules that will biochemically and functionally target CRMP2’s 
SUMOylation to reduce NaV1.7 currents and reverse neuropathic pain [99]. Mapping of hot 
spots of CRMP2 surface interaction with SUMOylation machinery may form the basis of 
future drug discovery campaigns. By disrupting the interaction between CRMP2 and E2 
SUMO conjugating enzyme Ubc9, NaV1.7 function can be reduced to offer pain relief [101]. 
CRMP2 may very well turn out to be a prized target as its additional post-translational 
modifications allow tuning of functions of another important nociceptive ion channel – the 
N-type voltage-gated calcium (CaV2.2) channel. For example, phosphorylation of CRMP2 
by cyclin-dependent kinase 5 promotes CaV2.2 surface expression and augments CaV2.2 
current density [102–105]. Thus, disruption of CRMP2 phosphorylation yields an additional 
therapeutic target. The generally restricted expression of CRMP2 in DRGs and in the dorsal 
horn of the spinal cord ideally situate CRMP2 for promoting continuity of pain signals. 
CRMP2 trafficking of multiple ion channels could allow for dual targeting of calcium and 
sodium signaling to produce antinociception. Whether the other four members of the CRMP 
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family couple to NaV1.7 is unknown except for a report demonstrating that CRMP1 interacts 
with NaV1.7 to mediate retrograde axonal signaling of the axon guidance molecule 
semaphorin 3A [106].
6. Targeting NaV1.7 - the road not yet taken
With the associated $635B cost of chronic pain to the US economy in 2012 [2] and the 
country’s aging baby-boomer population, chronic pain and novel therapeutics are in need of 
desperate attention by research and medical communities. As we have highlighted here, 
NaV1.7 has the correct biological function in gating threshold currents and the correct 
neuronal expression pattern in pain-sensing dorsal root ganglia sensory neurons to be ideally 
suited in the targeting of peripheral pain signaling [13]. Initially, similarity to the eight other 
voltage-gated sodium channels prevented efficient targeting without off-target effects on 
channels involved in cardiac function and cognition. However, there is reason for optimism 
that NaV1.7-targeted strategies will soon appear on market with no less than eight 
pharmaceutical companies and research groups reporting successful mitigation of pain using 
high-affinity and selective NaV1.7-targeted compounds in preclinical, Phase I, and Phase II 
clinical trials. Seminal studies by the Waxman group have brought NaV1.7 closer to 
personalized, genomically-guided treatment of patients with pain [3].
A number of research groups, including our own, have taken an alternative approach and 
attempted to classify modifiers of NaV1.7 channel expression and functional current levels. 
These strategies benefit from elucidation of new DRG subtypes separated by RNA 
sequencing and defining the interactome of NaV1.7. The goals of these studies are to 
selectively target pain-contributing neurons with minimal off-target effects. The spared nerve 
injury model of neuropathic pain produces a two-fold increase in NaV1.7 within the sciatic 
nerve [64]. If an accessory or trafficking protein of NaV1.7 can subtly modify how well the 
channel is anchored to the membrane, whether the channel can be targeted for degradation, 
or the rate at which the channel is inserted into the membrane, then pain relief can be 
achieved. Indeed, several groups have published promising results reversing chronic pain 
conditions in preclinical models of pain that are incompletely treated by conventional 
therapeutics.
Among these discussed protein partners of NaV1.7, we are most enthusiastic about targets 
involved in the dysregulation of NaV1.7 in preclinical models of chronic pain. Increased 
expression of Homer2, increased SUMOylation of CRMP2, and decreased expression of 
Nedd4–2 have each been observed in pain models and could be critical events preceding 
augmentation of NaV1.7 surface trafficking and threshold current production [51, 64, 72]. 
Targeting these proteins to restore their normal functions could then normalize NaV1.7 in 
painful diseases that are resistant to conventional therapeutics [2]. Each of these three 
proteins function at the plasma membrane where they contribute to trafficking or retention of 
functional NaV1.7. With NaV family proteins undergoing very slow turnover (roughly 13-
day turnover in mice), subtle modifications to NaV1.7 channel trafficking has the potential to 
produce effective and long-lasting treatments [47, 107].
Chew et al. Page 16
Biochem Pharmacol. Author manuscript; available in PMC 2020 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Clearly, NaV1.7 itself and modifiers of the channel have been validated as targets for control 
of pain signaling. In the last several years, the pain field has also begun to entertain the 
possibility that endogenous opioid signaling and NaV1.7 function are fundamentally linked 
at the level of the spinal cord [44]. This may elegantly allow NaV1.7-targeted approaches to 
have secondary effects on enhancing endogenous opioid production and promote pain-
relieving signaling pathways in DRGs. While incompletely explored and controversial, the 
link between endogenous opioid production and NaV1.7 DRG expression is another avenue 
by which to explore the ramifications of targeting NaV1.7-mediated signaling in pain. 
Carefully mining and traversing the diverging protein-protein roads may make all the 
difference in successfully developing a therapeutic to target NaV1.7 for chronic pain. The 
challenges ahead are lovely, dark and deep but given our inescapability from pain, it is 
imperative that academic and industry keep their efforts on drug discovery around NaV1.7 
signaling to fulfill a much-needed promise.
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Figure 1. Identified NaV1.7 Protein Interactors.
Schematic of sodium channel NaV1.7 protein interactors including synaptic and intracellular 
organelle localization. Proteins are identified by gene symbol, in approximate area near a 
functioning location. Protein abbreviations are as follows and classified by possible 
functioning locations: Plasma Membrane (Blue): Scn3b - Sodium channel subunit beta-3; 
Homer2 - Isoform 2 of Homer protein homolog 2; Rp2 - Isoform 2 of Protein XRP2; 
Plekhb1 - Isoform 2 of Pleckstrin homology domain-containing family B member 1; Tusc5 - 
Tumour suppressor candidate 5 homolog; Calb2 - Calretinin; Tmed10 - Transmembrane 
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emp24 domain-containing protein 10; Ntm – Neurotrimin; Mpp2 - Isoform 2 of MAGUK 
p55 subfamily member 2; Des - Desmin; Cdh2 - Cadherin-2; Ogt - Isoform 2 of UDP-N-
acetylglucosamine; Nfasc - Neurofascin; Mpdz - Isoform 2 of Multiple PDZ domain protein; 
Tln1 - Talin-1; Dsp - Desmoplakin; Slc4a8 - Isoform 2 of Electroneutral sodium bicarbonate 
exchanger 1; Slc7a5/Lat1 - Large neutral amino acids transporter small subunit 1; Ank3 - 
Ankyrin-3; Gprin1 - G protein-regulated inducer of neurite outgrowth 1; Syt2 - 
Synaptotagmin-2; Cytoplasm (Green): Bola2 - BolA-like protein 2; Psma7 - Proteasome 
subunit alpha type-7; Psma1 - Proteasome subunit alpha type-1; Homer2 - Isoform 2 of 
Homer protein homolog 2; Psma5 - Proteasome subunit alpha type-5; Psmb2 - Proteasome 
subunit beta type-2; Pebp1 - Phosphatidylethanolamine-binding protein 1; Plekhb1 - Isoform 
2 of Pleckstrin homology domain-containing family B member 1; Omp - Olfactory marker 
protein; Fabp7 - Fatty acid-binding protein; Psmb5 - Proteasome subunit beta type-5; 
Psmd12 - 26S proteasome non-ATPase regulatory subunit 12; Mlst8 - Target of rapamycin 
complex subunit LST8; Psma4 - Proteasome subunit alpha type-4; Psmb4 - Proteasome 
subunit beta type-4; Psmd4 - Isoform Rpn10B of 26S proteasome non-ATPase regulatory 
subunit 4; Rab1A - Ras-related protein Rab-1A; Calb2 - Calretinin; Ahsa1 - Activator of 90-
kDa heat-shock protein ATPase homolog 1; Tkt - Transketolase; Ddb1 - DNA damage-
binding protein 1; Des - Desmin; Ogt - Isoform 2 of UDP-N-acetylglucosamine; Sgk223 - 
Tyrosine-protein kinase SgK223; Slc7a5/Lat1 - Large neutral amino acids transporter small 
subunit 1; Dpysl2/Crmp2 - Dihydropyrimidinase-related protein 2/ Collapsin Response 
Mediator Protein 2; Nucleus (Brown): Bola2 - BolA-like protein 2; Psma7 - Proteasome 
subunit alpha type-7; Psma1 - Proteasome subunit alpha type-1; Psma5 - Proteasome subunit 
alpha type-5; Erh - Enhancer of rudimentary homolog; Psmb2 - Proteasome subunit beta 
type-2; Psmb5 - Proteasome subunit beta type-5; Psmd12 - 26S proteasome non-ATPase 
regulatory subunit 12; Psma4 - Proteasome subunit alpha type-4; Psmb4 - Proteasome 
subunit beta type-4; Psmd4 - Isoform Rpn10B of 26S proteasome non-ATPase regulatory 
subunit 4; Calb2 - Calretinin; Actr2 - Actin-related protein 2; Htatsf1 - HIV Tat-specific 
factor 1 homolog; Sart3 - Squamous cell carcinoma antigen recognized by T cells 3; Rbm10 
- Isoform 3 of RNA-binding protein 10; Tkt - Transketolase; Ddb1 - DNA damage-binding 
protein 1; Des - Desmin; Ogt - Isoform 2 of UDP-N-acetylglucosamine; Ahnak - Protein 
Ahnak; Sgk223 - Tyrosine-protein kinase SgK223; Mitochondria (Purple): Ndufv3; NADH 
dehydrogenase [ubiquinone] flavoprotein 3; Ndufb10 - NADH dehydrogenase [ubiquinone] 
1 beta subcomplex subunit 10; Apoo - Apolipoprotein O; Oxct1 - Succinyl-CoA:3-ketoacid 
coenzyme A transferase 1; Gpx4 - Isoform Cytoplasmic of Phospholipid hydroperoxide 
glutathione oxidase; Pccb - Propionyl-CoA carboxylase beta chain; Ogt - Isoform 2 of UDP-
N-acetylglucosamine; Mccc2 - Methylcrotonoyl-CoA carboxylase beta chain; Cytoskeleton 
(Light Pink): Flna - Filamin-A; Map2 - Microtubule-associated protein; Actr2 - Actin-
related protein 2; Akap12 - Isoform 2 of A-kinase anchor protein 12; Mpp2 - Isoform 2 of 
MAGUK p55 subfamily member 2; Camsap3 - Isoform 2 of calmodulin-regulated spectrin-
associated protein 3; Ppp1r9a - Protein Ppp1r9a; Tln1 - Talin-1; Dsp - Desmoplakin; Ank3 - 
Ankyrin-3; Dpysl2/Crmp2 - Dihydropyrimidinase-related protein 2/ Collapsin Response 
Mediator Protein 2; ER-Golgi-Endomembrane System -(Orange): Rp2 - Isoform 2 of Protein 
XRP2; Apoo - Apolipoprotein O; Rab1A - Ras-related protein Rab-1A; Ahsa1 - Activator of 
90-kDa heat-shock protein ATPase homolog 1; Wdr7 - WD repeat-containing protein 7; Tkt 
- Transketolase; Tmed10 - Transmembrane emp24 domain-containing protein 10; Lnp - 
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Protein lunapark; Agpat3 - 1-acyl-sn-glycerol-3-phosphate acyltransferase gamma; 
Extracellular/Synaptic (Dark Pink): Homer2 - Isoform 2 of Homer protein homolog 2; Fga - 
Isoform 2 of Fibrinogen alpha chain; Apoo - Apolipoprotein O; Psmd12 - 26S proteasome 
non-ATPase regulatory subunit 12
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Figure 2. In the absence of NaV1.7 activity, opioid-dependent analgesia relies on Nfat5-mediated 
facilitation of Penk mRNA.
Inhibition of NaV1.7 decreases intracellular sodium levels and leads to upregulation of Nfat5 
mRNA and its protein byproduct. Given that Nfat5 binds five consensus binding sites 
upstream of the Penk coding region, Nfat5 likely increases Penk mRNA expression. The 
arrow illustrates that peptides cleaved from Penk possibly activating these receptors on 
neurons (possibly on other cells). Complementary exploration of roles for opioid receptors 
suggest implication of both MOR and DOR in this analgesic mechanism, but the specifics 
remain controversial, with reports from distinct groups sometimes bearing contradicting 
results.
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Figure 3. CRMP2 modifications regulate NaV1.7 trafficking in normal and neuropathic pain 
conditions and prevention of CRMP2 SUMOylation reverses the expression of pain.
(A) Numb, a component of the clathrin-mediated endocytosis (CME) machinery, acts as a 
scaffold between CME and epidermal growth factor receptor substrate 15 (Eps15). 
Monoubiquitination of NaV1.7 by the E3 ubiquitin ligase Nedd4–2 tags it for endocytosis 
[64, 73]. Eps15 binds to monoubiquitinylated membrane proteins and induces membrane 
curvature. CRMP2 SUMOylation is prevented when CRMP2 phosphorylation by Cdk5 at 
S522 is also prevented [73]. Consequently, non SUMOylated CRMP2 has an enhanced 
interaction with Numb. The stoichiometry of how many subunits within the CRMP2 
tetramer are SUMOylated is unknonwn. (B) Cartoon depicting hypothesis of increased 
CRMP2 SUMOylation in neuropathic pain driving NaV1.7 function. In the unilateral spared 
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nerve injury (SNI), an injury that involves a lesion of two of the three terminal branches of 
the sciatic nerve (tibial and common peroneal nerves) leaving the remaining sural nerve 
intact, increased NaV1.7 protein and CRMP2 SUMOylation was noted in the ipsilateral 
spinal cord dorsal horn [72]. (C) Model of CRMP2 SUMOylation and control of NaV1.7. 
tat-CSM, cell penetrant version of CRMP2 SUMOylation motif (CSM) decoy peptide. The 
small ubiquitin-like modifier (SUMO), in a process called SUMOylation, covalently and 
reversibly tags an ~11 kD SUMO protein to lysine K374 in CRMP2. As with ubiquitination, 
a cascade of three enzymes, E1 (activating), E2 (conjugating) and E3 (ligase) produce an 
isopeptide bond between the C-terminal glycine of SUMOs 1–3 and an ε-amino group of a 
target lysine within a SUMO-binding motif on the acceptor protein. Ubc9 is an E2 enzyme 
that directly conjugates one or more of the 3 vertebrate SUMO proteins to target proteins, 
while the sentrin/SUMO-specific proteases (SENP 1 and SENP2) remove SUMOs, thus 
reversing the modification. A CRMP2 SUMOylation motif (CSM) “decoy” peptide 
interferes with cellular CRMP2 SUMOylation and decreases NaV1.7 trafficking and currents 
[76] while intrathecal injection of a cell penetrant version of the CSM peptide reversed nerve 
injury-induced thermal and mechanical hypersensitivity with no sedation or motor 
impairment in rats [76]; it is anticipated that small molecules, when developed, will mimic 
the peptide to achieve a similar silencing of NaV1.7 activity and pain.
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